Pediatrix Medical Group tops Q2 expectations, raises 2025 outlook

Published 05/08/2025, 11:26
 Pediatrix Medical Group tops Q2 expectations, raises 2025 outlook

FORT LAUDERDALE - On Tuesday, Pediatrix Medical Group, Inc. (NYSE:MD) reported second-quarter adjusted earnings per share of $0.53, exceeding analyst estimates of $0.42, while revenue reached $468.84 million compared to the consensus forecast of $464.37 million.

The healthcare provider’s strong performance was driven by a 6.4% increase in same-unit revenue, with neonatal intensive care unit (NICU) days rising 6.0% compared to the same period last year. The company’s total revenue of $468.8 million was down from $504.3 million in the prior-year period, primarily due to practice dispositions, but this was partially offset by the same-unit growth.

"Our second quarter operating results exceeded our forecast and reflect continuing strong neonatology patient volumes, stable payor mix, and careful operations management," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group.

Following the strong quarterly results, Pediatrix raised its full-year 2025 Adjusted EBITDA outlook from a previous range of $220 million to $240 million to a new range of $245 million to $255 million. The company reported Adjusted EBITDA of $73.2 million for the second quarter, up from $57.9 million in the prior-year period.

Same-unit revenue from net reimbursement-related factors increased by 3.5% compared to the prior-year period, reflecting higher patient acuity in hospital-based practices, improved collection activity, and increased administrative fees from hospital partners. Patient volume contributed an additional 2.9% to same-unit revenue growth.

The company ended the quarter with $224.7 million in cash and cash equivalents and generated $138.1 million in cash from continuing operations, compared to $109.3 million during the second quarter of 2024.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.